Chief Physician Specialty: Surgical treatment of gastrointestinal tumors, gastric stromal tumors, and surgical management of malignant intestinal obstruction. Professional Affiliations: Standing Committee Member of the Colorectal Cancer Prevention and Treatment Committee, Beijing Cancer Prevention and Treatment Society; Secretary-General of the Cancer Science Popularization Committee, Beijing Anti-Cancer Association; Vice Chairman of the Humanities Science Branch, China Sexology Association; Recipient of the Beijing Municipal Hospital Authority Cultivation Program and one Beijing Outstanding Talent Project. Representative Publications: 1. Chen N, J AA, Wu A. Nonoperative management of gastrointestinal malignancies in era of neoadjuvant treatment. Chin J Cancer Res. 2023;35(1):44-57. (First Author) 2. Chen N, Zhao M, Yao Y, Wang L, Peng Y, Sun T, et al. Neoadjuvant chemotherapy with capecitabine combined with oxaliplatin for mid-low locally advanced rectal cancer with negative mesorectal fascia: Long-term outcomes of a prospective trial (PKUCH-R03 trial). Chin J Cancer Res. 2024;36(4):410-20. (First Author) 3. Sun L, Xu Y, Chen N, Zhang C, Wu A, Wang H, et al. Chinese herbal medicine (JianPi-BuShen) and completion rate of adjuvant chemotherapy for patients with stage II and III colon cancer: A randomized clinical trial. Eur J Cancer. 2024;213:115109. (Co-first Author) 4. Sun Z, Shi M, Xia J, Li X, Chen N, et al. HDAC and MEK inhibition synergistically suppresses HOXC6 and enhances PD-1 blockade efficacy in BRAFV600E-mutant microsatellite stable colorectal cancer. J Immunother Cancer. 2025 Jan 11;13(1):e010460. doi: 10.1136/jitc-2024-010460. PMID: 39800382; PMCID: PMC11749543. (Co-first Author) 5. Zhang Z, Liu S, Xu T, Chen N, et al. Tumor suppressor SLC9A2 inhibits colorectal cancer metastasis and reverses immunotherapy resistance by suppressing angiogenesis. J Exp Clin Cancer Res. 2025 Jun 5;44(1):172. doi: 10.1186/s13046-025-03422-7. PMID: 40474298; PMCID: PMC12139321. (Co-first Author)